Kestra Medical Technologies filed a Form S-1 for an initial public offering on February 10, 2025. The Kirkland, Washington, medical-device company subsequently priced its IPO at $17 per share, completed the offering on March 7, 2025, and now trades on Nasdaq under KMTS. Its core product is a prescription wearable cardioverter-defibrillator—not a smartwatch or ordinary heart-monitoring patch.
What happened to Kestra’s IPO?
Kestra Medical Technologies, Ltd., a Bermuda-incorporated company headquartered at 3933 Lake Washington Blvd. NE, Suite 200, Kirkland, Washington, filed its registration statement with the U.S. Securities and Exchange Commission on February 10, 2025. The preliminary filing proposed a Nasdaq Global Market listing under the symbol KMTS, but it left the number of shares and price blank because those terms had not yet been set. The filing is available in the SEC Form S-1 and its filing index.
The eventual IPO terms were more specific:
| Milestone | Verified detail |
|---|---|
| IPO pricing | 11,882,352 common shares at $17 per share |
| IPO closing | March 7, 2025 |
| Overallotment | Underwriters bought 1,782,352 additional shares at $17 on March 14, 2025 |
| Current listing | Nasdaq: KMTS |
Those closing details and the company’s later public-company status are reported in Kestra’s fiscal 2026 Form 10-K. Therefore, describing Kestra as merely “about to go public” would be outdated.
What Kestra makes
A wearable cardioverter-defibrillator
Kestra’s flagship ASSURE Wearable Cardioverter Defibrillator (WCD) continuously monitors a patient’s heart rhythm when that person is at elevated risk of sudden cardiac arrest. If the system detects a specified life-threatening ventricular arrhythmia, it is designed to deliver a defibrillation shock.
Free tools Windows power users keep installed
One-click scans. No signup required.
#1 Best Overall
- Included Components: Heartstart Onsite Aed Defibrillator, Battery, Adult Smart Pads Cartridge, Setup
This is a prescription therapeutic medical device. It is not a consumer fitness tracker, smartwatch, or standard ECG patch that only records information for later review. The distinction matters: ASSURE is intended to provide treatment as well as monitoring, under its approved use.
The broader Cardiac Recovery System
Kestra presents ASSURE as part of an integrated Cardiac Recovery System that includes:
- the ASSURE WCD;
- a patient mobile application;
- Kestra CareStation, a remote patient-management platform;
- Heart Alert Services; and
- ASSURE Assist, designed to notify emergency services after a therapeutic shock.
Kestra said the U.S. Food and Drug Administration granted premarket approval for the ASSURE WCD on July 27, 2021, after clinical trials were completed in March 2020. The company fully commercially launched the product in August 2022, according to its SEC filings.
How Kestra’s business model works
Kestra primarily leases the ASSURE WCD to patients month to month as part of the Cardiac Recovery System rather than relying only on one-time device sales. It bills Medicare, Medicaid, private insurers, other healthcare organizations, and patients for applicable coinsurance and deductibles.
That model creates recurring-service potential, but it also makes revenue dependent on the healthcare payment system. Kestra must secure prescriptions, obtain authorization, document medical necessity, process claims, collect reimbursement, and support patients while devices are in use. Reusable equipment also requires inventory, logistics, servicing, and reconditioning between patients.
HCPCS code and coverage variability
Kestra’s 2026 annual report says the ASSURE WCD is reimbursable under HCPCS code K0606. The company also says most large national payors maintain coverage policies for WCD therapy. Coverage and payment rates can nevertheless vary by insurer, state, geography, contract terms, and regional Medicare administrative decisions. FDA approval makes a device legally marketable; it does not guarantee that every patient qualifies or that every prescription will be paid at a commercially attractive rate.
Rank #2
- Versatile tool for enhancing couple experiences
- Portable offers convenient operation
- Sleek design ensures comfortable wear
- Promotes comfort and connection between partners
- Made to deliver a steady and soothing sensation CEAADFFE
Financial picture when Kestra filed
At the time of the February 2025 filing, Kestra was commercial-stage but loss-making. Contemporary reporting by GeekWire said revenue rose from $7.6 million in fiscal 2023 to $27.8 million in fiscal 2024, while net losses widened from $84.2 million to $94.1 million. The fiscal years ended in April.
| Fiscal year | Revenue | Net loss |
|---|---|---|
| 2023 | $7.6 million | $84.2 million |
| 2024 | $27.8 million | $94.1 million |
The figures show why revenue growth should not be confused with profitability. A medical-device company can be expanding commercial placements while spending heavily on manufacturing, clinical evidence, sales, reimbursement operations, software, and patient support.
PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchGeekWire also reported that Kestra had raised approximately $496 million from investors, including a $196 million financing round in July 2024. The S-1 said IPO proceeds were intended for research and development, additional clinical trials and evidence generation, working capital, and general corporate purposes. The preliminary filing did not establish the final offering size or proceeds.
What happened after the IPO?
Kestra’s fiscal 2026 Form 10-K reported a net loss of $131.6 million for the year ended April 30, 2026, compared with a $113.8 million net loss for fiscal 2025. The company therefore remained substantially unprofitable after becoming public.
The filing also identifies continued dependence on the ASSURE WCD and related services. Product adoption, reimbursement, and the ability to scale operations remain central to the company’s financial outlook. Current corporate information is available through Kestra’s investor-relations site and its SEC filings page.
Why reimbursement and adoption are the key business questions
Prescription and workflow friction
Physicians must identify appropriate patients, prescribe the therapy, and incorporate monitoring into care workflows. Patients must wear the system as directed, respond to alerts, and tolerate its practical demands. Noncompliance or discomfort can reduce the therapy’s value even when coverage is available.
Rank #3
- ESSENTIAL LIFE-SAVING ACCESSORIES : The Fast Response Kit includes all the essential supplies typically needed for patient care and personal protection
- WHAT’S IN THE BOX: 2 pairs of hypoallergenic nitrile gloves, pocket breathing mask, paramedic scissors, chest hair razor, large extra-absorbent paper towel, and zippered pouch
- CONVENIENTLY COMPACT: Dimensions: 9.5 x 5.5 x 1.75 inches; Weight: 4.8 ounces
- PEACE OF MIND: Accessories include 1-year warranty
- Please contact Philips directly with any questions regarding the performance or operation of your HeartStart Products. Replacements are permitted for warranty purposes only
Coverage is not automatic
Insurers can impose documentation requirements, medical-necessity criteria, authorization procedures, or payment limits. A reduction in reimbursement or a restrictive coverage policy can affect both prescription volume and revenue per patient.
Leasing brings operating obligations
A recurring lease can produce revenue beyond the initial placement, but Kestra must maintain a functioning fleet, manage shipping and returns, recondition equipment, provide technical support, and protect patient data. The company also relies on third-party manufacturers and suppliers, exposing it to production, quality, and supply-chain disruptions.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Ownership and public-company risks
Bain Capital remained a major shareholder. As of April 30, 2026, Bain beneficially owned approximately 43% of Kestra’s common shares and voting power, according to the Form 10-K. That concentration can give Bain substantial influence over board composition, equity issuance, and major corporate transactions. A “controlled company” governance classification reflects concentrated voting power; it does not mean Bain owns all of Kestra.
Other risks disclosed by the company include product liability, misuse, cybersecurity and patient-data exposure, regulatory changes, competition from existing WCD products and other treatment options, reliance on limited-source suppliers, and continued operating losses. Company statements about market size or comparative performance should be treated as management claims unless supported by independently reviewed evidence.
What the IPO means for investors
Kestra offers exposure to a specialized medical-device and digital-health business with a commercial product, FDA approval, and a reimbursement-based recurring model. The counterweight is substantial execution risk: the company has remained loss-making, depends heavily on one core product platform, and must convert prescriptions into reliably reimbursed therapy while controlling service and manufacturing costs.
For anyone researching KMTS, the most important documents are the company’s SEC filings, which show fiscal-year losses, reimbursement disclosures, ownership concentration, and changes in share count. The February 2025 S-1 explains the original public-market story; the March 2025 closing terms and fiscal 2026 Form 10-K explain what happened afterward.
The Bottom Line
Kestra is now a public, commercial-stage medtech company—not a pre-IPO startup. Its investment case rests on wider adoption and reimbursement of the ASSURE wearable defibrillator, while persistent losses, coverage variability, operational demands, competition, and Bain Capital’s voting influence remain material risks.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Recommended Free Tools
